xenon.png
Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss First Quarter 2024 Financial Results and Provide Corporate Update
May 02, 2024 16:01 ET | Xenon Pharmaceuticals Inc.
VANCOUVER, British Columbia, May 02, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company, today announced it will report its first...
xenon.png
Xenon Pharmaceuticals Showcases XEN1101 at the American Academy of Neurology 2024 Annual Meeting
April 16, 2024 08:30 ET | Xenon Pharmaceuticals Inc.
VANCOUVER, British Columbia, April 16, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company, announced two oral presentations...
xenon.png
Xenon Pharmaceuticals to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
April 10, 2024 08:30 ET | Xenon Pharmaceuticals Inc.
VANCOUVER, British Columbia, April 10, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present...
xenon.png
Xenon Pharmaceuticals to Present at the 23rd Annual Needham Virtual Healthcare Conference
April 04, 2024 16:01 ET | Xenon Pharmaceuticals Inc.
VANCOUVER, British Columbia, April 04, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present...
xenon.png
Xenon Pharmaceuticals to Present at Stifel 2024 Virtual CNS Days
March 12, 2024 16:01 ET | Xenon Pharmaceuticals Inc.
VANCOUVER, British Columbia, March 12, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present...
xenon.png
Xenon Pharmaceuticals to Present at Leerink Partners Global Biopharma Conference 2024
March 05, 2024 16:01 ET | Xenon Pharmaceuticals Inc.
VANCOUVER, British Columbia, March 05, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present...
xenon.png
Xenon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
February 29, 2024 16:01 ET | Xenon Pharmaceuticals Inc.
XEN1101 Phase 3 epilepsy program continues to progress with X-TOLE2 and X-TOLE3 in focal onset seizures and X-ACKT in primary generalized tonic-clonic seizures; completion of patient enrollmentĀ in...
xenon.png
Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update
February 22, 2024 16:01 ET | Xenon Pharmaceuticals Inc.
VANCOUVER, British Columbia, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced it will report its fourth...
xenon.png
Xenon Pharmaceuticals Outlines Key Milestone Opportunities for 2024
January 08, 2024 08:00 ET | Xenon Pharmaceuticals Inc.
Completion of Patient Enrollment in XEN1101 Phase 3 X-TOLE2 Clinical Trial in Focal Onset Seizures Anticipated in Second Half of 2024 XEN1101 Phase 3 Program in Major Depressive Disorder Planned for...
xenon.png
Xenon Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 03, 2024 08:30 ET | Xenon Pharmaceuticals Inc.
VANCOUVER, British Columbia, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present...